+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cell-Based Assays: Technologies and Global Markets

  • PDF Icon

    Report

  • 234 Pages
  • July 2022
  • Region: Global
  • BCC Research
  • ID: 4667529
Description Jump to:

Report Scope



This report is an update of an earlier report of the same title. This report offers a comprehensive analysis of the global cell-based assays market. Segmentation is based on product, type/application and end user. Based on type/application, the market is segmented as drug discovery for validating drug targets/lead profiling assays, absorption, distribution, metabolism, and excretion (ADME) toxicity assays and basic research. The regional markets covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

The report provides a detailed overview and analysis of the present and future global market for cell-based assay techniques. The report analyzes in detail currently available cell-based assays and their markets. Industry growth drivers, restraints and opportunities are also discussed in detail. The report also provides information on competitive landscape, elaborative company profiles and the impact of COVID-19 on the market.

Report Includes

  • 63 tables
  • An up-to-date review of the global markets for cell-based assays and related technologies
  • Analyses of the global market trends, with historic sales data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
  • Highlights of the current and future potential in the market for cell-based assays, and areas of focus to forecast this market into various segments and sub-segments
  • Estimation of the actual market size for cell-based assays, revenue forecast, and corresponding market share analysis based on product, type/application, end user and geographic region
  • Market assessment of the cell-based assays available and currently being used, new developments, spending trends, and revenue prospects for cell-based assays in the pharmaceutical industry
  • Coverage of major issues involved in the research and development (R&D) of more effective cell-based approaches for drug discovery
  • In-depth information on increasing investments on R&D activities, key technology issues, industry specific challenges, major types of end-user markets, and COVID-19 implications on the progress of this market
  • Competitive analysis of the market for cell-based assays and updated information on the mergers, acquisitions, collaborations and recent developments during the 2020-2022 period
  • Descriptive company profiles of the leading global players, including Becton, Dickinson & Company, Charles River Laboratories, General Electric Healthcare, Merck KGaA and Thermo Fisher Scientific Inc.

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing this Study
  • What's New in this Update?
  • Scope of Report
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
  • Introduction
  • Overview: Cell-Based Assays
  • Drug Discovery
  • Tools for Drug Discovery
  • High-Content Screening
  • High-Content Screening Products
  • Data Analysis
  • Cell-Based Screening
  • Proliferation Assays
  • Apoptosis Assays
  • Activation Assays
  • Assays to Measure Gene Expression
  • Proof of Concept for Cell-Based Assays
  • Cell-Based Assays and Technology Trends
  • Advancements in Cell-Based Assays
  • Novel Cell-Based Assay Using Organoids, Scaffolds/Hydrogels and Organs-On-A-Chip
  • Spheroids for Drug Development
  • Label-Free Cell-Based Assay Technology Using Biolayer Interferometry
  • Lineage Sequencing for Mutational Analysis and Cancer-Based Studies
  • Evaluation of Hantavirus Replication Using In-Cell Western Assay
  • Quantitative Cell-Based Assay Using a High-Content Analysis Platform
  • High-Throughput Single-Cell Transcriptome Sequencing
  • Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy
  • Luciferase-Based High-Throughput Screening Assay
  • Functionally Relevant Morphological Profiling for Mesenchymal Stromal Cells
  • G Protein-Coupled Receptors
  • Gpcrs: a Potent Class of Drug Targets
  • Gpcr Drugs
  • Developments
  • Cell-Based Assays: Screening Ion Channels
Chapter 4 Assays for Drug Discovery
  • Cell-Based Approaches for Adme/Tox Screening
  • Market Opportunities
  • Adme and Toxicity Screening
  • Multiplexed Cell-Based Assays
  • High-Throughput Imaging-Based Platform for Cell-Based Assays
  • Cell Assays in Today's Drug Discovery Process
  • Label-Free Cellular Assays: the Relevant Future of Drug Discovery
  • Conclusion
Chapter 5 Cell-Based Assays: Current Technologies
  • Factors in Cell-Based Assay Development
  • Reporter Gene Technology
  • Cell-Based Assays for Studying Protein-Protein Interactions
  • Cell-Based Protein-Fragment Complementation Assays
  • Measuring Calcium Signaling
  • Cell-Based Label-Free Approaches
  • Label-Free Detection
  • Companies
  • Thermo Fisher
  • Cellsensor
  • Lanthascreen
  • Molecular Devices
  • Automation and Miniaturization
  • Cell Patterning
  • Cell-Based Assays and Physiological Relevance
  • Cell-Based Assays and Multiplexing
  • Developing Reporter Assays
  • Reporter Assays and Multiplexing
  • Ultrahigh-Throughput Screening
  • Development of the Pathhunter Assay
  • High-Content Screening Technology
  • Imaging Cells for Cell-Based Assays
  • Microscopic Visualization of Cells
  • Quantum Dots
  • Label-Free Imaging
  • Investigational New Studies in Drug Development
  • Role of Adme in Drug Design
  • Prodrug Strategies
  • Molecular Modeling
  • Summary
  • Limitations of Cell-Based Assays in the Risk Assessment Process
  • Bottlenecks in Cell-Based Screening
  • Methods to Improve Throughput in Cell-Based Assays
  • New Technologies
  • Datachip
  • Bind Technology
  • Miniaturization of Biological Assays
  • Microfluidic Cell Culture Systems for Drug Research
  • Conclusion
Chapter 6 Commercialization of Cell-Based Assays
  • Role of Cell-Based Assays
  • Demand for Cell-Based Assays
  • Drug Discovery and Cell-Based Assays
  • Opportunities for Market Adoption
  • Measuring Cell Proliferation
  • Companies Offering Cell Proliferation Assays
  • Move Toward Therapies With Stem and Immune Cells
  • Cell-Based Screening Assays
  • Orphan Receptors
  • Summary
Chapter 7 Market Dynamics
  • Factors Affecting the Market for Cell-Based Assays
  • Market Drivers
  • Market Restraints
Chapter 8 Impact of Covid-19
  • Introduction
  • Outbreak
  • Covid-19 Symptoms
  • Progression of Covid-19
  • Incubation Period
  • Epidemiology
  • Collaboration Between Organizations and Governments
  • Spread of Disease
  • Impact of Covid-19 on the Cell-Based Assay Market
Chapter 9 Global Market for Cell-Based Assays by Application
  • Current Market Overview
  • Cell-Based Assays
  • Market for Cell-Based Assays
  • Applications
  • Drug Discovery
  • Basic Research
  • Adme and Toxicology
Chapter 10 Global Market for Cell-Based Assays by Segment
  • Consumables
  • Instruments
  • Software
  • Services
Chapter 11 Cell-Based Assays Market by End-user
  • Biotechnology and Pharmaceutical Companies
  • Academic and Research Institutes
  • Contract Research Organizations
Chapter 12 Global Market for Cell-Based Assays by Region
  • Global Market Overview
  • Regional Markets
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World (Row)
Chapter 13 Competitive Landscape
  • Mergers, Acquisitions, and Collaborations
  • Recent Developments
  • Competitive Analysis
Chapter 14 Company Profiles
  • Agilent Technologies Inc.
  • Becton, Dickinson & Co.
  • Bioivt
  • Bio-Rad Laboratories
  • Cell Biologics
  • Cell Biolabs Inc.
  • Cell Signaling Technology Inc.
  • Charles River
  • Corning, Inc.
  • Danaher
  • Discoverx Corp.
  • Enzo Life Sciences
  • Evotec AG
  • Fujifilm Cellular Dynamics Inc. (Fcdi)
  • Ge Healthcare
  • Lonza
  • Merck Kgaa
  • Oncolmmunin
  • Perkinelmer
  • Promega Corp.
  • Thermo Fisher Scientific
List of Tables
Summary Table A: Global Market for Cell-Based Assays, Through 2027
Summary Table B: Global Market for Cell-Based Assays, by Application, Through 2027
Table 1: Uses of Cell-Based Assays by Area
Table 2: Types of Cell-based Assays
Table 3: Apoptotic Markers
Table 4: Proof of Concept for Cell-Based Assays
Table 5: Materials and Manufacturers of Hydrogels, by Type
Table 6: Minimum Requirements for Organ-on-a-Chip Units, by Type
Table 7: HCS Instrumentation Available in the Market, by Company
Table 8: HCS Informatics Tools Available in the Market, by Application
Table 9: Selected High-Throughput Instruments Available in the Market
Table 10: Assay Methods Used to Study GPCRs
Table 11: GPCR Primary Screening Assays
Table 12: Key GPCR Targeting Drugs
Table 13: Key Companies with GPCR Products
Table 14: Omeros’ GPCRs and Their Indications
Table 15: Biological Assay Systems for the Evaluation of Cytochrome P450 Enzyme Isoforms
Table 16: Types of Hepatocyte Assay Systems
Table 17: Types of ADME Assays
Table 18: Common Types of Toxicity Assays
Table 19: Traditional Methods of ADME/Tox Testing
Table 20: Conventional In Vitro ADME/Tox Screening Methods
Table 21: Applications of Label-Free Assays
Table 22: Factors for Cell-Based Assay Development
Table 23: Approaches to Cell-Based Systems for Drug Screening
Table 24: Thermo Fisher’s Products
Table 25: Thermo Fisher’s Cell-Based Technologies
Table 26: List of Current Confocal HCS Platforms
Table 27: Widefield HCS Platforms, by Type
Table 28: List of Studies for Filing an Investigational New Drug Application
Table 29: List of Studies for Clinical Filings
Table 30: List of Existing Cell-Based Assay Technologies
Table 31: Limitations of Cell-Based Assays
Table 32: Biological Applications for High-Content Analysis
Table 33: Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020
Table 34: U.S. NIH Funding for Various Disease Conditions, 2014-2020
Table 35: COVID-19 Clinical Symptom Distribution
Table 36: COVID-19 Confirmed Cases and Deaths, by WHO Region, June 15, 2022
Table 37: Global Market for Cell-Based Assays, Through 2027
Table 38: Global Market for Cell-Based Assays, by Application, Through 2027
Table 39: Global Market for Cell-Based Assays in Drug Discovery, by Region, Through 2027
Table 40: Global Market for Cell-Based Assays for Basic Research, by Region, Through 2027
Table 41: Global Market for Cell-Based Assays in ADME and Toxicology, by Region, Through 2027
Table 42: Global Market for Cell-Based Assays, by Segment, Through 2027
Table 43: Global Market for Consumables, by Region, Through 2027
Table 44: Global Market for Instruments, by Region, Through 2027
Table 45: Global Market for Software, by Region, Through 2027
Table 46: Global Market for Services, by Region, Through 2027
Table 47: Global Market for Cell-Based Assays, by End User, Through 2027
Table 48: Global Market for Cell-Based Assays Used by Pharmaceutical and Biotechnology Companies, by Region, Through 2027
Table 49: Global Market for Cell-Based Assays Used by Academic and Research Institutes, by Region, Through 2027
Table 50: Global Market for Cell-Based Assays Used by Contract Research Organizations, by Region, Through 2027
Table 51: Growth Drivers of the Cell-Based Assay Market
Table 52: Global Market for Cell-Based Assays, by Region, Through 2027
Table 53: North American Market for Cell-Based Assays, by Country, Through 2027
Table 54: European Market for Cell-Based Assays, by Country, Through 2027
Table 55: Asia-Pacific Market for Cell-Based Assays, by Country, Through 2027
Table 56: Mergers, Acquisitions and Collaborations, 2019-2022
Table 57: Competitive Analysis of the Market for Cell-Based Assays, 2021
Table 58: Becton, Dickinson & Company: Business Segment
Table 59: Charles River Laboratories: Business Segments
Table 60: Danaher: Business Segment
Table 61: Thermo Fisher Scientific Inc.: Business Segments
List of Figures
Summary Figure A: Global Market for Cell-Based Assays, 2019-2027
Summary Figure B: Global Market for Cell-Based Assays, by Application, 2019-2027
Figure 1: Projected Global Aging Population (65 Years and Above), 1990-2050
Figure 2: Drug Discovery Process Steps
Figure 3: Process Flow for Patient-Derived Organoid Cell Assay
Figure 4: Basic Architecture of Organ-on-a-Chip Systems
Figure 5: Cell Viability and Kinase Assays Used to Measure Change in ATP Levels
Figure 6: Distribution of Top 20 Diseases for Mesenchymal Stromal Cell-Related Clinical Studies, 2021
Figure 7: Distribution of Approved Drugs with Unique GPCRs, 2019
Figure 8: Personalized Medicines on the Market, 2008-2020
Figure 9: Global Pharmaceutical R&D Spending, 2010-2019
Figure 10: Global Market for Cell-Based Assays, by Application, 2019-2027
Figure 11: Global Market Shares of Cell-Based Assays, by Application, 2021
Figure 12: Global Market for Cell-Based Assays in Drug Discovery, by Region, 2019-2027
Figure 13: Global Market for Cell-Based Assays for Basic Research, by Region, 2019-2027
Figure 14: Phase Transition Success Rates and Likelihood of Approval from Phase I for All Diseases, All Modalities, 2011-2020
Figure 15: Global Market for Cell-Based Assays in ADME and Toxicology, by Region, 2019-2027
Figure 16: Global Market for Cell-Based Assays, by Segment, 2019-2027
Figure 17: Global Market Shares of Cell-Based Assays, by Segment, 2021
Figure 18: Global Market for Consumables, by Region, 2019-2027
Figure 19: Global Market for Instruments, by Region, 2019-2027
Figure 20: Global Market for Software, by Region, 2019-2027
Figure 21: Global Market for Services, by Region, 2019-2027
Figure 22: Global Market for Cell-Based Assays, by End User, 2019-2027
Figure 23: Global Market Shares of Cell-Based Assays, by End User, 2021
Figure 24: Biopharmaceuticals R&D Spending, 2010-2024
Figure 25: Global Market for Cell-Based Assays Used by Pharmaceutical and Biotechnology Companies, by Region, 2019-2027
Figure 26: Global Market for Cell-Based Assays for Academic and Research Institutes, by Region, 2019-2027
Figure 27: Global Market for Cell-Based Assays Used by Contract Research Organizations, by Region, 2019-2027
Figure 28: Global Market for Cell-Based Assays, by Region, 2019-2027
Figure 29: Global Market Shares of Cell-Based Assays, by Region, 2021
Figure 30: North American Market for Cell-Based Assays, by Country 2019-2027
Figure 31: U.S. Market for Cell-Based Assays, 2019-2027
Figure 32: Canadian Market for Cell-Based Assays, 2019-2027
Figure 33: European Market for Cell-Based Assays, by Country, 2020-2027
Figure 34: U.K. Market for Cell-Based Assays, 2019-2027
Figure 35: German Market for Cell-Based Assays, 2019-2027
Figure 36: French Market for Cell-Based Assays, 2019-2027
Figure 37: Italian Market for Cell-Based Assays, 2019-2027
Figure 38: Spanish Market for Cell-Based Assays, 2019-2027
Figure 39: Rest of the European Market for Cell-Based Assays, 2019-2027
Figure 40: Asia-Pacific Market for Cell-Based Assays, by Country, 2020-2027
Figure 41: Chinese Market for Cell-Based Assays, 2019-2027
Figure 42: Japanese Market for Cell-Based Assays, 2019-2027
Figure 43: Indian Market for Cell-Based Assays, 2019-2027
Figure 44: Rest of Asia-Pacific Market for Cell-Based Assays, 2019-2027
Figure 45: Rest of the World Market for Cell-Based Assays, 2019-2027
Figure 46: Becton, Dickinson & Company: Annual Revenue, 2019-2021
Figure 47: Becton, Dickinson & Company: Market Shares, by Region, 2021
Figure 48: Becton, Dickinson & Company: Market Shares, by Business Segment, 2021
Figure 49: Charles River Laboratories: Annual Revenue, 2019-2021
Figure 50: Charles River Laboratories: Market Share, by Region, 2021
Figure 51: Charles River Laboratories: Market Share, by Segment, 2021
Figure 52: Danaher: Annual Revenue, 2019-2021
Figure 53: Danaher: Diagnostic Segment Market Shares, by Region, 2021
Figure 54: Danaher: Market Shares, by Business Segment, 2021
Figure 55: Eurofins Pharma Discovery Services (Eurofins DiscoverX Products): Annual Revenue, 2019-2021
Figure 56: Eurofins DiscoverX Products: Market Share, by Region, 2021
Figure 57: General Electric Healthcare: Annual Revenue, 2019-2021
Figure 58: General Electric Healthcare: Market Shares, by Region/Country, 2021
Figure 59: General Electric Healthcare: Market Shares, by Business Segment, 2021
Figure 60: Lonza: Annual Revenue, 2020 and 2021
Figure 61: Lonza: Market Shares, by Business Segment, 2021
Figure 62: Merck KGaA: Annual Revenue, 2019-2021
Figure 63: Merck KGaA: Market Share, by Region, 2021
Figure 64: Merck KGaA: Market Share, by Segment, 2021
Figure 65: PerkinElmer: Annual Revenue, 2019-2021
Figure 66: PerkinElmer: Market Share, by Region/Country, 2021
Figure 67: PerkinElmer: Market Shares, by Business Unit, 2021
Figure 68: Thermo Fisher Scientific Inc.: Annual Revenue, 2019-2021
Figure 69: Thermo Fisher Scientific Inc.: Market Shares, by Region, 2021
Figure 70: Thermo Fisher Scientific Inc.: Market Shares, by Business Segment, 2021"

Executive Summary

Cell-based assays are basically experiments used to study, analyze and understand how live cells respond to external factors. These assays are commonly used in drug discovery for validating drug targets. They are also used in lead profiling, in basic research for understanding cell signaling and function, and for ADME toxicity testing.

It has been observed that pharmaceutical R&D expenses place a significant burden on the healthcare industry because the drug discovery and development entails substantial time and resources to recognize an effective drug that can progress to clinical trial. This long process has a success rate of around 10%-12%, that is only 10% of the drugs get approval after undergoing clinical trials. So, using cell-based assays will be helpful in the initial step of drug discovery as it will help to screen the compounds. Also, with the advancement of technologies, automated processes are being used for drug screening and development purposes. Studies have indicated that using methods such as cell-based assays earlier in the drug development cycle will help in eliminating the toxic products and avoid late - stage drug failures and financial losses. Since live cells are used in cell-based assays, they are biologically more relevant and will also help in replacing animal testing.

There is a need to grow product pipelines for companies. The benefits of cell-based assays over in vivo methods have led to their increased use in drug discovery. In vitro cell-based methods also offer flexibility and cost advantages. In addition, advancements in automation and high-throughput techniques are offering support to this market.

The increasing prevalence of chronic diseases, aging population and increased healthcare expenditure are driving the drug discovery market. There are many diseases that still do not have any approved therapies for cures and depend only on symptomatic management, e.g., amyotrophic lateral sclerosis, cirrhosis, non-alcoholic steatohepatitis, etc. Therefore, cell-based assays will be beneficial for such indications. More research and the increasing prevalence of cancer as well as neurogenerative diseases, such as Alzheimer’s, Parkinson’s disease and other rare indications, will also be contributing factors for the market.

Personalized drug treatment is becoming a reality. In response to the rise in the incidence of a number of diseases and an aging population, the drug discovery industry is developing new and more efficacious drugs based on specific biomarker signatures. These drugs can be developed and tested to meet specific endpoints with the use of cell-based assays.

Companies Mentioned

  • Agilent Technologies Inc.
  • Becton, Dickinson & Co.
  • Bioivt
  • Bio-Rad Laboratories
  • Cell Biologics
  • Cell Biolabs Inc.
  • Cell Signaling Technology Inc.
  • Charles River
  • Corning, Inc.
  • Danaher
  • Discoverx Corp.
  • Enzo Life Sciences
  • Evotec AG
  • Fujifilm Cellular Dynamics Inc. (Fcdi)
  • Ge Healthcare
  • Lonza
  • Merck Kgaa
  • Oncolmmunin
  • Perkinelmer
  • Promega Corp.
  • Thermo Fisher Scientific

Table Information

Report AttributeDetails
No. of Pages234
PublishedJuly 2022
Forecast Period2022 - 2027
Estimated Market Value ( USD ) in 2022 $ 29.2 Billion
Forecasted Market Value ( USD ) by 2027 $ 47.3 Billion
Compound Annual Growth Rate10.2%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Cell-based Assay Market Report by Product and Services, Technology, Application, End-User, and Region 2024-2032 - Product Image

Cell-based Assay Market Report by Product and Services, Technology, Application, End-User, and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Cell-based Assays Market Report and Forecast 2024-2032 - Product Image

Cell-based Assays Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Cell Based Assays - Global Strategic Business Report - Product Image

Cell Based Assays - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Cell-based Assays Global Market Report 2024 - Product Image

Cell-based Assays Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Cell Based Assay & High Content Screening Markets. Forecasts by User and Product. With Executive and Consultant Guides. 2024 to 2028 - Product Image

Cell Based Assay & High Content Screening Markets. Forecasts by User and Product. With Executive and Consultant Guides. 2024 to 2028

  • Report
  • 276 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.